Mar. 22, 2021—Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people.
‘Risks of Alzheimer’s Disease in Adults with Down Syndrome’ webinar and introduction to research study is March 29
Mar. 8, 2021—The Vanderbilt Kennedy Center and the Down Syndrome Association of Middle Tennessee will co-sponsor a webinar, “Risks of Alzheimer's Disease in Adults with Down Syndrome and Introduction to a Research Study,” on Monday, March 29, from 7 to 8 p.m. CT.
Dec. 16, 2020—Christos Constantinidis has been appointed professor in the Department of Biomedical Engineering beginning Jan. 1, 2021. At Vanderbilt, he also will be a member of the university’s Brain Institute and the Vision Research Center.
Nov. 16, 2020—Changes in connectivity in the brain’s white matter may be a novel neuroimaging biomarker for assessing Alzheimer’s disease progression.
Jerri Rook is awarded the Alzheimer’s Drug Discovery Foundation’s prestigious Melvin R. Goodes prize
Nov. 2, 2020—Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research.
Sep. 10, 2020—Angela Jefferson, PhD, professor of Neurology and director of the Vanderbilt Memory and Alzheimer’s Center, has been awarded a $3.7 million, three-year grant from the National Institute on Aging (NIA) to support establishment of a prospective NIA-funded Alzheimer’s Disease Research Center (ADRC) at Vanderbilt University Medical Center.
Sep. 3, 2020—Combining studies of genetically diverse mouse populations and human data led to the identification of a gene associated with cognitive decline and brain changes in Alzheimer’s disease.
Dec. 12, 2019—A drug used to treat and prevent HIV/AIDS is showing promise as a potential therapy for Alzheimer’s disease.
Dec. 5, 2019—Poorly functioning AMPARs have been linked to a wide range of neurological and psychiatric disorders including seizures, Alzheimer’s disease, major depression and autism spectrum disorder. Understanding how AMPARs are formed and operate is essential for the rational design of pharmacological compounds that, by tuning AMPAR activity up or down, could improve treatment of these conditions.
May. 28, 2019—Vanderbilt's inaugural Alzheimer’s Disease Research Day drew more than 100 attendees to hear faculty lectures on subjects ranging from diet to brain modeling, take in short “data blitzes” on individual areas of research, and visit a 35-station poster session.
May. 7, 2018—The APOE gene, the strongest genetic risk factor for Alzheimer’s disease, may play a more prominent role in disease development among women than men, according to new research from the Vanderbilt Memory and Alzheimer’s Center.
Mar. 27, 2018—The cognitive impairment that affects patients who survive a stay in the ICU does not appear to have a similar mechanism to Alzheimer’s disease, Vanderbilt researchers have discovered.